Product Description
Laboratorios Sophia S.A de C.V. is developing pro-122, a topical ADRB2 Antagonist,ADRA2A Agonist,CA Inhibitor for Glaucoma. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03966365)
Mechanisms of Action: ADRB2 Antagonist,ADRA2A Agonist,CA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Laboratorios Sophia S.A de C.V.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Glaucoma, Open-Angle|Hypertension
Phase 1: Glaucoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| PRO-122/I | P1 |
Completed |
Glaucoma |
2019-08-30 |
50% |
2019-12-17 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| PRO-122LATAM | P3 |
Terminated |
Glaucoma, Open-Angle |
2024-10-30 |
30% |
2025-03-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| CONFORTK | P3 |
Completed |
Hypertension|Glaucoma, Open-Angle |
2017-03-01 |
2019-03-21 |
Treatments |